Study Evaluating IMA-026 in Healthy Subjects

Wyeth

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Biological: IMA-026

Study type: Interventional

Funder types: Industry

Identifiers

NCT00517348

3192K1-1000

Details and patient eligibility

About

To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMA-026 administered subcutaneously (SC) or intravenously (IV) in healthy adults.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

• Healthy men and women ages 18 - 50
• Body weight greater than or equal to 50 kilograms
• Nonsmoker or fewer than 10 cigarettes per day
• No serious infection, i.e., requiring hospitalization or IV antibiotics, or an upper respiratory infection within 1 month before dosing

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind